Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031
Bitget2026/10/23 13:02- Tempus AI expanded its collaboration with Bristol Myers Squibb under a multiyear oncology data licensing agreement running through 2031.
- The agreement makes Bristol Myers Squibb one of its largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development.
- Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Executives reveal new monetization strategy for Meta AI: Muse is ad-free but charges for enterprise services, and takes a commission on shopping through AI agents
Meta AI chief Alexandr Wang stated that Muse is available to regular users for free and that Meta has no plans to introduce advertisements. Meta plans to offer paid services to enterprises, but specific pricing and launch timeline have not been disclosed. He also mentioned that Meta's proprietary infrastructure, security systems, and data centers provide Muse with a competitive advantage that is difficult for rivals to replicate.

Report: The Trump administration plans to remove some tariffs on Canadian goods to boost the midterm elections
According to media reports, the Trump administration plans to exempt certain Canadian agricultural and forestry products from the 50% tariff, with an announcement as early as this Friday. To maintain the overall scale of tariffs, this tax reduction may be offset by imposing additional tariffs on other Canadian goods. The move is mainly intended to help Maine Senator Susan Collins retain her seat in the midterm elections, while it could also benefit other Republican candidates in trade-dependent states.

VWO ETF Closes Flat
IWF ETF Falls 0.4%